Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Sorrento Therapeutics Inc patents


Recent patent applications related to Sorrento Therapeutics Inc. Sorrento Therapeutics Inc is listed as an Agent/Assignee. Note: Sorrento Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Sorrento Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sorrento Therapeutics Inc-related inventors


 new patent  Linked dual antibodies conjugated at a hinge region

There is disclosed methods for derivatizing and conjugating two hinge-containing antibody molecules. There is further disclosed derivatized and conjugated hinge-containing antibody molecules.. ... Sorrento Therapeutics Inc

Anti-infective binding proteins that bind aip2

There is disclosed compositions and methods relating to or derived from anti-aip2 antibodies. More specifically, there is disclosed fully human antibodies that bind aip2, aip2-binding fragments and derivatives of such antibodies, and aip2-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Fully human anti-cxc chemokine receptor 5 (cxcr5) antibodies

There is disclosed compositions and methods relating to or derived from anti-cxcr5 antibodies. More specifically, there is disclosed fully human antibodies that bind cxcr5, cxcr5-binding fragments and derivatives of such antibodies, and cxcr5-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Antibody drug conjugates having derivatives of amatoxin as the drug

There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an adc (antibody drug conjugate).. . ... Sorrento Therapeutics Inc

Antibody therapeutics that bind stat3

The present disclosure provides anti-stat3 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.. ... Sorrento Therapeutics Inc

Antigen binding proteins that bind wisp1

There is disclosed compositions and methods relating to or derived from anti-wisp1 antibodies. More specifically, there is disclosed fully human antibodies that bind wisp1, wisp1-binding fragments and derivatives of such antibodies, and wisp1 binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Antibody therapeutics that bind cd38

There is disclosed compositions and methods relating to or derived from anti-cd38 antibodies. More specifically, there is disclosed fully human antibodies that bind cd38, cd38-antibody binding fragments and derivatives of such antibodies, and cd38-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Antibody therapeutics that bind cd123

There is disclosed compositions and methods relating to or derived from anti-cd123 antibodies. More specifically, there is disclosed fully human antibodies that bind cd123, cd123-antibody binding fragments and derivatives of such antibodies, and cd123-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Antigen binding proteins that bind c-met

There is disclosed compositions and methods relating to or derived from anti-c-met antibodies. More specifically, there is disclosed fully human antibodies that bind c-met, c-met-binding fragments and derivatives of such antibodies, and c-met-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

C-met antibody drug conjugate

There is disclosed an antibody drug conjugate (adc) having an igg antibody that binds to a c-met target conjugated at both cys sites in the hinge region of an igg antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-met adc.. ... Sorrento Therapeutics Inc

Antigen binding proteins that bind pd-l1

There is disclosed compositions and methods relating to or derived from anti-pd-l1 antibodies. More specifically, there is disclosed fully human antibodies that bind pd-l1, pd-l1-binding fragments and derivatives of such antibodies, and pd-l1-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin

There is disclosed a calicheamicin antibody drug conjugate comprising a linking amidoacetyl group covalently bound to a sugar moiety on calicheamicin or linking to sulfur atom on calicheamicin through disulfide bond.. . ... Sorrento Therapeutics Inc

Chemically-locked bispecific antibodies

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the igg class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific igg class antibody having a linkage region joined together with bio-orthogonal click chemistry.. ... Sorrento Therapeutics Inc

Safety for treating cancers with a glycosylated chimeric antibody to egfr

There is disclosed a chimeric cetuximab-like monoclonal antibody (cmab009 mab) having at least 80% nana glycosylation terminal sialic acid at an n-glycosylation site asn297 and a glycosylation pattern of gal-α(2,3/6)-gal. The disclosed cmab009 monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of seq id no. ... Sorrento Therapeutics Inc

08/31/17 / #20170247443

Safety and efficacy with a cho cell glycosylated chimeric antibody to tnf

There is disclosed a chimeric infliximab-like monoclonal antibody having at least 80% nana glycosylation terminal sialic acid and a glycosylation pattern of gal-α(2,3/6)-gal that binds to tumor necrosis factor alpha (tnf). The disclosed infliximab-like monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of seq id no. ... Sorrento Therapeutics Inc

08/17/17 / #20170233476

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

08/10/17 / #20170226215

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

08/10/17 / #20170224835

Antibody drug conjugates

There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a cys or a lys residue. ... Sorrento Therapeutics Inc

07/06/17 / #20170190736

Antibody drug conjugates

There is disclosed a dolastatin derivative, conjugated to an antibody, comprising a dolastatin derivative moiety of formula iv.. . ... Sorrento Therapeutics Inc

06/29/17 / #20170182161

Antigen binding proteins that bind pd-l1

There is disclosed compositions and methods relating to or derived from anti-pd-l1 antibodies. More specifically, there is disclosed fully human antibodies that bind pd-l1, pd-l1-binding fragments and derivatives of such antibodies, and pd-l1-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

06/15/17 / #20170166644

Fully human antibodies that bind to vegfr2

There is disclosed compositions and methods relating to anti-vegfr2 antibodies. More specifically, there is disclosed fully human antibodies that bind vegfr2, vegfr2-binding fragments and derivatives of such antibodies, and vegfr2-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

04/27/17 / #20170112878

Programmable universal cell receptors and method of using the same

. . The present invention provides programmable universal cell receptors (pucrs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The pucrs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest. ... Sorrento Therapeutics Inc

02/09/17 / #20170037129

Antibody therapeutics that bind cd147

. . There is disclosed compositions and methods relating to or derived from anti-cd147 antibodies. More specifically, there is disclosed fully human antibodies that bind cd147, cd147-binding fragments and derivatives of such antibodies, and cd147-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc

01/26/17 / #20170022273

Antibody therapeutics that bind lag3

There is disclosed compositions and methods relating to or derived from anti-lag3 antibodies. More specifically, there is disclosed fully human antibodies that bind lag3, lag3-antibody binding fragments and derivatives of such antibodies, and lag3-binding polypeptides comprising such fragments. ... Sorrento Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Sorrento Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sorrento Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###